


Q1 What is your primary area of expertise?


Answered: 99 Skipped: 1



ANSWER OPTIONS	ANSWERS	
Hematology	82.83%	82
Pediatric Hematology-Oncology	16.16%	16
Genetics	1.01%	1
Immunology	0.00%	0
Pathology	0.00%	0
TOTAL		99

S2 How many years have you been working in the field of hematology (including hematology residency training)?


Responded: 100 Skipped: 0



ANSWER OPTIONS	ANSWERS	
1–5 years	20.00%	20
5–10 years	21.00%	21
More than 10 years	59.00%	59
TOTAL		100

S3 Have you previously received structured training in the field of cellular therapies?


Responded: 98 Skipped: 2



ANSWER OPTIONS		ANSWERS	
Yes		30.61%	30
No		69.39%	68
TOTAL			98

S4 Which organization do you currently work for?

Responded: 100 Skipped: 0




ANSWER OPTIONS	ANSWERS	
State University Hospital	46.00%	46
Foundation University Hospital	22.00%	22
City Hospital	14.00%	14
Education and Research Hospital	8.00%	8
Private Hospital	10.00%	10
TOTAL		100

S5 How many patients with pre-B-ALL, B-NHL (subtypes), myeloma, and AML were treated at your clinic in the past year?

Answered: 100 Skipped: 0

Survey on the Use of CAR T-Cell Products in Clinical Trials




Survey on the Use of CAR T-Cell Products in Clinical Trials

	A. < 10	B. 10–25	C. 25–50	D. >50	TOTAL
preB-ALL	36.36% 36	37.37% 37	12.12% 12	14.14% 14	99
B-NHL	10.99% 10	14.29% 13	39.56% 36	35.16% 32	91
Myeloma	8.05% 7	12.64% 11	27.59% 24	51.72% 45	87
AML	20.62% 20	35.05% 34	28.87% 28	15.46% 15	97

S6 What are the relapse rates for patients with these disease groups treated at your clinic over the past year?

Responded: 97 Skipped: 3

Survey on the Use of CAR T-Cell Products in Clinical Trials




Survey on the Use of CAR T-Cell Products in Clinical Trials

	A. < 5%	B. 15–25%	C. 25–35%	D. >45%	TOTAL
preB-ALL	24.21% 23	34.74% 33	30.53% 29	10.53% 10	95
B-NHL	20.00% 18	50.00% 45	26.67% 24	3.33% 3	90
Myeloma	14.12% 12	29.41% 25	31.76% 27	24.71% 21	85
AML	17.71% 17	36.46% 35	33.33% 32	12.50% 12	96

What are your response rates to current salvage therapies (chemotherapy, monoclonal antibodies, targeted therapies, and KIT) in your patients with S7 relapse?

Responded: 97 Skipped: 3

Survey on the Use of CAR T-Cell Products in Clinical Trials




Survey on the Use of CAR T-Cell Products in Clinical Trials

	A. < 10%	B. 10–25%	C. 25–45%	D. >45%	TOTAL
preB-ALL	5.26% 5	18.95% 18	46.32% 44	29.47% 28	95
B-NHL	3.41% 3	6.82% 6	38.64% 34	51.14% 45	88
Myeloma	0.00% 0	3.70% 3	27.16% 22	69.14% 56	81
AML	4.30% 4	13.98% 13	48.39% 45	33.33% 31	93

Q8 If you had access to CAR T cells within the scope of a national and/or international clinical trial, would you want to use them in your relapsed patients?


Respondents: 100 Skipped: 0



ANSWER OPTIONS	ANSWERS	
Yes	98.00%	98
No	2.00%	2
TOTAL		100

S9 Would you prefer to use CAR T-cell therapy in patients with relapsed disease in the first-line setting or in later-line settings?


Responded: 100 Skipped: 0



ANSWER OPTIONS	ANSWERS	
I use it in first-line treatment	35.00%	35
I use it in later stages of treatment	61.00%	61
I have no opinion on this	4.00%	4
TOTAL		100

Can S10 CAR T cells be used as standard therapy alone or during the transition to transplantation after the first remission in high-risk patients?


Answered: 100 Skipped: 0



ANSWER OPTIONS	ANSWERS	
Yes	66.00%	66
No	20.00%	20
I have no opinion on this.	14.00%	14
TOTAL		100

S11 Do you believe you have sufficient knowledge regarding the indications for use, clinical application, and product characteristics (quality/control tests, functional analyses, etc.) of CAR T-cell products?


Responded: 100 Skipped: 0



ANSWER OPTIONS		ANSWERS	
Yes		24.00%	24
No		76.00%	76
TOTAL			100

S12 What infrastructure is available at your institution regarding the production and/or clinical use of advanced cellular therapies (you may select more than one option)?

Responded: 94 Skipped: 6



ANSWER OPTIONS	ANSWERS	
Bone Marrow Transplantation Unit	89.36%	84
Multidisciplinary Clinical Team	79.79%	75
GMP Laboratory and Experienced Staff	17.02%	16
Clinical Research Center	64.89%	61
Clinical Research Ethics Committee	79.79%	75
Total Respondents: 94		